Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK14 | O94921 | 8/20 | 0.51 |
| ▸ | CCNY | Q8ND76 | 8/20 | 0.51 |
| ▸ | JAK2 | O60674 | 4/20 | 0.47 |
| ▸ | TYK2 | P29597 | 4/20 | 0.47 |
| ▸ | JAK1 | P23458 | 3/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 2/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.43 |
| ▸ | CDK9 | P50750 | 1/20 | 0.43 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.43 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.40 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.40 |
| ▸ | TAS1R2 | Q8TE23 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4488401 | 0.89 | CDK14 (0.48) | CDK14CCNYJAK2TYK2JAK1 | |
| SCHEMBL954955 | 0.89 | KMT2A (0.51) | CDK14CCNYJAK2TYK2JAK1 | |
| SCHEMBL12288164 | 0.87 | CDK14 (0.53) | CDK14CCNYJAK2TYK2JAK1 | |
| SCHEMBL8261624 | 0.87 | CDK14 (0.50) | CDK14CCNYJAK2TYK2JAK1 | |
| SCHEMBL1070972 | 0.86 | KMT2A (0.55) | CDK14CCNYJAK2TYK2JAK1 | |
| SCHEMBL8262556 | 0.84 | CDK14 (0.48) | CDK14CCNYJAK2TYK2JAK1 | |
| SCHEMBL8212885 | 0.82 | TYK2 (0.68) | CDK14CCNYJAK2TYK2JAK1 | |
| SCHEMBL954966 | 0.81 | CDK14 (0.55) | CDK14CCNYJAK2TYK2JAK1 | |
| SCHEMBL25649653 | 0.81 | KMT2A (0.49) | CDK14CCNYJAK2TYK2JAK1 | |
| SCHEMBL8261502 | 0.81 | CDK14 (0.55) | CDK14CCNYJAK2TYK2JAK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1846393-B1 | 4-(2,6-DICHLOROBENZOYLAMINO)-1H-PYRAZOLE-3-CARBOXYLIC ACID PIPERIDIN-4-YLAMIDE ACID ADDITION SALTS AS KINASE INHIBITORS | ASTEX THERAPEUTICS LTD (GB) | 2020-02-19 | — | — | EP | disclosed |
| US-8293767-B2 | 4-(2,6-dichloro-benzoylamino)-1H-pyrazole-3-carboxylic acid piperidin-4-ylamide acid addition salts as kinase inhibitors | ASTEX THERAPEUTICS LIMITED (GB) | 2012-10-23 | — | — | US | disclosed |
| US-20110274616-A1 | 4-(2,6-DICHLORO-BENZOYLAMINO)-1H-PYRAZOLE-3-CARBOXYLIC ACID PIPERIDIN-4-YLAMIDE ACID ADDITION SALTS AS KINASE INHIBITORS | ASTEX THERAPEUTICS LIMITED (GB) | 2011-11-10 | — | — | US | disclosed |
| US-8013163-B2 | 4-(2,6-dichloro-benzoylamino)-1H-pyrazole-3-carboxylic acid piperidin-4-ylamide acid addition salts as kinase inhibitors | ASTEX THERAPEUTICS LIMITED (GB) | 2011-09-06 | — | — | US | disclosed |
| US-8013163-B2 | 4-(2,6-dichloro-benzoylamino)-1H-pyrazole-3-carboxylic acid piperidin-4-ylamide acid addition salts as kinase inhibitors | ASTEX THERAPEUTICS LIMITED (GB) | 2011-09-06 | — | — | US | disclosed |
| US-20090318500-A1 | 4-(2, 6-Dichloro-benzoylamino)-1H-pyrazole-3-carboxylic acid (1-methanesulphonyl-piperidin-4-yl)-amide for the Treatment of Cancer | ASTEX THERAPEUTICS LIMITED (GB) | 2009-12-24 | — | — | US | disclosed |
| US-20090318500-A1 | 4-(2, 6-Dichloro-benzoylamino)-1H-pyrazole-3-carboxylic acid (1-methanesulphonyl-piperidin-4-yl)-amide for the Treatment of Cancer | ASTEX THERAPEUTICS LIMITED (GB) | 2009-12-24 | — | — | US | disclosed |
| US-20090012124-A1 | 4-(2,6-dichloro-benzoylamino)-1H-pyrazole-3-carboxylic acid piperidin-4-ylamide acid addition salts as kinase inhibitors | ASTEX THERAPEUTICS LIMITED (UK) | 2009-01-08 | — | — | US | disclosed |
| US-20090012124-A1 | 4-(2,6-dichloro-benzoylamino)-1H-pyrazole-3-carboxylic acid piperidin-4-ylamide acid addition salts as kinase inhibitors | ASTEX THERAPEUTICS LIMITED (UK) | 2009-01-08 | — | — | US | disclosed |
| WO-2007129066-A1 | 4- (2,6-DICHLORO-BENZOYLAMINO) -1H-PYRAZOLE-3-CARBOXYLIC ACID (1-METHANESULPHONYL-PIPERIDIN-4-YL) -AMIDE FOR THE TREATMENT OF CANCER | ASTEX THERAPEUTICS LIMITED (GB) | 2007-11-15 | — | — | WO | disclosed |
| WO-2006077426-A2 | 4- (2, 6-DICHLOROBENZOYLAMINO) -lH-PYRAZOLE-3 -CARBOXYLIC ACID PIPERIDIN- 4 -YLAMID ACID ADDITION SALTS AS KINASE INHIBITORS | ASTEX THERAPEUTICS LIMITED (GB) | 2006-07-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110274616-A1 | 4-(2,6-DICHLORO-BENZOYLAMINO)-1H-PYRAZOLE-3-CARBOXYLIC ACID PIPERIDIN-4-YLAMIDE ACID ADDITION SALTS AS KINASE INHIBITORS | MAP4K2, MAPKAPK2, MAP4K1 | CDK14 295/4885CCNY 1971/4885JAK2 30/4885 |
| US-20090012124-A1 | 4-(2,6-dichloro-benzoylamino)-1H-pyrazole-3-carboxylic acid piperidin-4-ylamide acid addition salts as kinase inhibitors | MAP4K2, MAPKAPK2, MAP4K1 | CDK14 295/4885CCNY 1971/4885JAK2 30/4885 |
| US-20090318500-A1 | 4-(2, 6-Dichloro-benzoylamino)-1H-pyrazole-3-carboxylic acid (1-methanesulphonyl-piperidin-4-yl)-amide for the Treatment of Cancer | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, CA5A, PDK4 | CDK14 392/4885CCNY 789/4885JAK2 1760/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.